Cookies 🍪

This site uses cookies that need consent. Learn more

Skip to content

Condition update published on

AVROBIO ends its gene therapy trial for Fabry disease

Share:

We are sad to announce that the pharmaceutical company AVROBIO has made the difficult decision to deprioritize its gene therapy trial for Fabry disease. It is another in a line of disappointments for

new therapies in the last year and it is hard on the Fabry community that we support.

If you need to speak to a member of the Support and Advocacy Team, please call 0345 389 9901.

You can read the full press release from AVROBIO here.

More condition posts